Elevance Health, Inc. (ELV)
(Delayed Data from NYSE)
$502.42 USD
-1.47 (-0.29%)
Updated Jul 23, 2024 04:00 PM ET
After-Market: $506.86 +4.44 (0.88%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$502.42 USD
-1.47 (-0.29%)
Updated Jul 23, 2024 04:00 PM ET
After-Market: $506.86 +4.44 (0.88%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth A Momentum B VGM
Zacks News
Medpace Holdings, Inc. (MEDP) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Medpace (MEDP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Humana (HUM) Ties Up With PsychArmor for Better Veteran Care
by Zacks Equity Research
Humana's (HUM) subsidiaries team up with PsychArmor to enhance veteran care, offering specialized training at 23 senior primary care centers in Texas, thereby attracting more members of the targeted community to the centers.
Here's Why You Should Retain HealthEquity (HQY) Stock for Now
by Zacks Equity Research
HealthEquity's (HQY) sustained strength in HSAs raises optimism about the stock.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
AxoGen's (AXGN) New Launch to Aid Peripheral Nerve Protection
by Zacks Equity Research
AxoGen (AXGN) announces the full launch of its Avive+ Soft Tissue Matrix to provide comprehensive solutions for nerve protection.
Here's Why You Should Add Ecolab (ECL) to Your Portfolio Now
by Zacks Equity Research
Ecolab's (ECL) focus on research and development raises optimism about the stock
Teladoc (TDOC) Harnesses AI for Diabetes Care, Stock Rises 6.7%
by Zacks Equity Research
AI can help Teladoc (TDOC) to streamline healthcare delivery, making it more efficient and scalable.
Humana's (HUM) CenterWell Expands in Louisiana With New Centers
by Zacks Equity Research
Humana's (HUM) CenterWell unit is likely to benefit from the opening of four new centers in the Baton Rouge and New Orleans areas in Louisiana, thus enhancing healthcare access for local seniors.
Elevance Health (ELV) Rallies 11.8% YTD: More Room to Run?
by Zacks Equity Research
Elevance Health's (ELV) performance benefits from new contract wins, a strong Carelon segment and recovering Medicaid business.
Universal Health (UHS) Gains 28% in a Year: What Lies Ahead?
by Zacks Equity Research
Universal Health (UHS) remains well-poised for growth on the back of growing patient volumes, acquisitions and a commendable financial position.
Are Medical Stocks Lagging DURECT (DRRX) This Year?
by Zacks Equity Research
Here is how Durect (DRRX) and Elevance Health (ELV) have performed compared to their sector so far this year.
Here's Why Elevance Health (ELV) is a Strong Growth Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Elevance Health (ELV) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Elevance Health (ELV) Stock Jumps 6.1%: Will It Continue to Soar?
by Zacks Equity Research
Elevance Health (ELV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Should You Invest in the iShares U.S. Healthcare Providers ETF (IHF)?
by Zacks Equity Research
Sector ETF report for IHF
Icon PLC (ICLR) Soars 4.3%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Icon PLC (ICLR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Why Elevance Health (ELV) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Elevance Health (ELV) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
UnitedHealth Unit (UNH) Wins Medicaid Deal to Serve Kansas
by Zacks Equity Research
UnitedHealth Group (UNH) receives a contract from the State of Kansas to provide enhanced care to beneficiaries of the KanCare program and gain a greater Medicaid customer base.
Icon PLC (ICLR) Up 6.6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Icon PLC (ICLR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Elevance (ELV) Rises 14.9% YTD: What Lies Ahead for Investors?
by Zacks Equity Research
Elevance (ELV) continues to focus on increasing shareholder value with consistent dividend payouts and stock repurchases.
Here's Why Elevance Health (ELV) is a Strong Growth Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Elevance Health (ELV) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Is Elevance Health (ELV) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Elevance Health (ELV) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
If You Invested $1000 in Elevance Health a Decade Ago, This is How Much It'd Be Worth Now
by Zacks Equity Research
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.